Prostacyclin (PGI2): New aspects of an old substance in the treatment of critically ill patients

Intensive Care Medicine

Volumn 23, Issue 2, 1997, Pages 146-158

  Scheeren, T ^a   Radermacher, P ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN;

ABDOMINAL PAIN; ALLERGIC ASTHMA; BLOOD FLOW; CRITICAL ILLNESS; DIARRHEA; FLUSHING; HEADACHE; HEART SURGERY; HEMODIALYSIS; HUMAN; HYPOTENSION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PULMONARY HYPERTENSION; REVIEW; SEPSIS; SIDE EFFECT; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION; VOMITING; ANIMAL; DRUG EFFECT; HEMODYNAMICS; INTENSIVE CARE; PHYSIOLOGY;

ANIMALS; CRITICAL CARE; EPOPROSTENOL; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0030615190     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050309     Document Type: Review

References (103)

1. Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665
2. 2, J Appl Physiol 45: 408-413
3. Gryglewski R, Korbut R, Ocetkiewicz A (1978) Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 273: 765-767
4. Coleman RA, Smith WL, Narumiya S (1994) VIII. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46: 205-229
5. Vane JR, Botting RM (1995) Pharmacodynamic profile of prostacyclin. Am J Cardiol 75: 3A-10A
6. 2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase. Am J Physiol 270:H1342-H1349
7. Jahr J, Eklund U, Grände P-O (1995) In vivo effects of prostacyclin on segmental vascular resistances, on myogenic reactivity, and on capillary fluid exchange in cat skeletal muscle. Crit Care Med 23: 523-531
8. Jones G, Hurley JV (1984) The effects of prostacyclin on the adhesion of leukocytes to injured vascular endothelium. J Pathol 142: 51-59
9. w-nitro-L-arginine on early events following lipopolysaccharide injection: observations in the hamster cheek pouch microcirculation. Int J Microcirc Clin Exp 15: 170-180
10. Reed MK, Taylor BJ, Smith G, Phan T, Myers SI (1990) Splanchnic prostanoid production: effect of hemorrhagic shock. J Surg Res 48: 579-583
11. 2 formation is increased in human sepsis syndrome. Am Rev Respir Dis 144: 1095-1101
12. Myers SI, Hernandez R (1992) Oxygen free radical regulation of rat splanchnic blood flow. Surgery 112: 347-354
13. Myers SI, Hernandez R Horton J (1993) Endotoxic shock has differential effects on renal and splanchnic eicosanoid synthesis. Prostaglandins Leukot Essent Fatty Acids 49: 509-513
14. 2 and prostacyclin with regard to cardiovascular and organ functions in early septic shock in man. Eur Surg Res 19: 65-77
15. Suttorp N, Galanos C, Neuhof H (1987) Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am J Physiol 253:C384-C390
16. 2 from the splanchnic bed. J Trauma 30: 993-998
17. Seibert K, Masferrer J, Zhang Y, Gregory S, Olson G, Hauser S, Leahy K, Perkins W, Isakson P (1995) Medialion of inflammation by cyclooxygenase-2. Agents Actions [Suppl 46]:41-50
18. Herschman HR, Xie W, Reddy S (1995) Inflammation, reproduction, cancer and all that . .. . The regulation and role of the inducible prostaglandin synthase. Bioessays 17: 1031-1037
19. Masferrer JL, Zweifel BS, Seibert K, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375-1379
20. Myers SI, Horton JW, Hernandez R, Walker PB, Vaughan WG (1994) Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion. Prostaglandins 47: 137-150
21. 2) by pentoxifylline from human vascular tissue. Arzneimittelforschung/Drug Res 32: 1315-1318
22. Araki H, Lefer AM (1980) Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol 238:H176-H181
23. Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE. Gasic GP (1978) Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200: 52-54
24. Lefer AM, Tabas J, Smith EF (1980) Salutary effects of prostacyclin in endotoxic shock. Pharmacology 21: 206-212
25. Araki H, Lefer AM (1980) Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res 47: 757-763
26. Ogletree ML, Lefer AM, Smith JB, Nicolaou KC (1979) Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 56: 95-103
27. Szekeres L, Pataricza J, Szilvássy Z, Udvary É, Végh A (1991) Cardioprotection: endogenous protective mechanisms promoted by prostacyclin. Basic Res Cardiol 86: 215-221
28. Henriksson P, Edhag O, Wennmalm Å (1985) Prostacyclin infusion in patients with acute myocardial infarction. Br Heart J 53: 173-179
29. Schrör K, Woditsch I, Strobach H, Schröder H (1991) Interactions between nitric oxide and prostacyclin in myocardial ischemia and endothelial cell cultures. Basic Res Cardiol 86: 176-181
30. Harbrecht BG, Stadler J, Demetris AJ, Simmons RL. Billiar TR (1994) Nitric oxide and prostaglandins interact to prevent hepatic damage during murine endotoxemia. Am J Physiol 266:G1004-G1010
31. Gong S, Ai Z, Zhou Y (1995) Protective effects of prostacyclin on acute necrotizing pancreatitis and its renal damage in rats. Chung Hua Wai Ko Tsa Chih 33: 197-200
32. Mashima S, Shirakami G, Mitsuyoshi A, Nakagami M, Morimoto T, Terasaki M, Nakao K, Yamabe H, Yamaoka Y, Ozawa K (1996) Evaluation of the protective effect of a novel prostacyclin analog on mesenteric circulation following warm ischemia. Eur Surg Res 28: 14-25
33. Hooper TL, Thomson DS, Jones MT, Cook L, Owen S, Wilkes S, Woodcock A, Webster AH, Hasleton P, Campbell CS, Rahman AN, McGregor CGA (1990) Amelioration of lung ischemic injury with prostacyclin. Transplantation 49: 1031-1035
34. Arroyo CM, Wade JV, Ichimori K, Nakazawa H (1994) The scanvenging of hydroxyl radical ( OH) by a prostacyclin analogue, taprostene. Chem Biol Interact 91: 29-38
35. Crutchley DJ, Conanan LB, Que BG (1994) Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-α and interleukin-1β in human monocytic THP-1 cells. J Pharmacol Exp Ther 271: 446-451
36. Eisenhut T, Sinha B, Gröttrup-Wolfers E, Semmler J, Siess W, Endres S (1993) Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 26: 259-264
37. Jörres A, Luttman W, Scholz P, Thierauch K-H, Gahl GM, Topley N, Frei U, Blitstein-Willinger E (1994) Specific inhibition of tumour necrosis factor in endotoxin-stimulated mononuclear leukocytes by the prostacyclin analogue iloprost. Clin Intensive Care 5: 296-302
38. Gaskill HV, Sirinek KR, Levine BA (1982) Prostacyclin increases gastric mucosal blood flow via cyclic AMP. J Surg Res 33: 140-145
39. Konturek SJ, Robert A (1982) Cytoprotection of canine gastric mucosa by prostacyclin: possible mediation by increased mucosal blood flow. Digestion 25: 155-163
40. Brinkmann A, Wolf C-F, Berger D, Kneitinger E, Neumeister B, Büchler M, Radermacher P, Seeling W, Georgieff M (1996) Perioperative endotoxemia and bacterial translocation during major abdominal surgery. Evidence for the protective effect of endogenous prostacyclin? Crit Care Med 24: 1293-1301
41. Hernandez R, Myers I (1993) Prostacyclin regulates splanchnic blood flow during early hemorrhage/reperfusion injury. Prostaglandins Leukot Essent Fatty Acids 48: 401-405
42. Landow L, Andersen LW (1994) Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol Scand 38: 626-639
43. Seelig RF, Kerr JC, Hobson RW, Machiedo GW (1981) Prostacyclin (epoprostenol) - its effects on canine splanchnic blood flow during hemorrhagic shock. Arch Surg 116: 428-430
44. Rasmussen I, Arvidsson D, Zak A, Haglund U (1992) Splanchnic and total body oxygen consumption in experimental fecal peritonitis in pigs: effects of dextran and iloprost. Circ Shock 36: 299-306
45. 2) increases apparent liver blood flow in man. Prostaglandins Leukot Essent Fatty Acids 10: 449-454
46. Imhoff M, Mork C, Lehner JH, Löhlein D (1995) Effect of prostacyclin on hepatic venous oxygen saturation after liver resection (abstract). Intensive Care Med 21:S185
47. Reinelt H, Eichelbrönner O, Mezödi M, Georgieff M, Radermacher P (1995) Prostacyclin for the treatment of hepatic failure after resolution of septic shock. Clin Intensive Care 6: 290-292
48. Mythen MG, Webb AR (1994) The role of gut mucosal hypoperfusion in the pathogenesis of post-operative organ dysfunction. Intensive Care Med 20: 203-209
49. Radermacher P, Buhl R, Santak B, Klein M, Kniemeyer HW, Becker H, Tarnow J (1995) The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 21: 414-421
50. Eichelbrönner O, Reinelt H, Wiedeck H, Mezödy M, Rossaint R, Georgieff M, Radermacher P (1996) Aerosolized prostacyclin and inhaled nitric oxide in septic shock - different effects on splanchnic oxygenation? Intensive Care Med 22: 880-887
51. Pittet J-F, Lacroix J-S, Gunning K, Laverriere M-C, Morel DR, Suter PM (1990) Prostacyclin hut not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure. Chest 98: 1467-1472
52. 2-consumption and skin microcirculation after cardiac surgery. Can J Anaesth 39: 1023-1029
53. Krausz MM, Utsunomiya T, Feuerstein G, Wolfe JHN, Shepro D, Hechtman HB (1981) Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 67: 1118-1125
54. Ditter H, Matthias FR, Voss R, Lohmann E (1988) Beneficial effects of prostacyclin in a rabbit endotoxin shock model. Thromb Res 51: 403-415
55. Demling RH, Smith M, Gunther R, Gee M, Flynn J (1981) The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery 89: 257-263
56. Bihari D, Smithies M, Gimson A, Tinker J (1987) The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 317: 397-403
57. Bihari DJ, Tinker J (1988) The therapeutic value of vasodilator prostaglandins in MOF associated with sepsis. Intensive Care Med 15: 2-7
58. Smithies M, Bihari DJ (1993) Delivery dependent oxygen consumption: asking the wrong questions and not getting any answers. Crit Care Med 21: 1622-1626
59. De Backer D, Berre J, Zhang H, Kahn RJ, Vincent J-L (1993) Relationship between oxygen uptake and oxygen delivery in septic patients: effects of prostacyclin versus dobutamine. Crit Care Med 21: 1658-1664
60. Wendon JA, Harrison PM, Keays R, Gimson AE, Alexander G, Williams R (1991) Arterial-venous pH differences and tissue hypoxia in patients with fulminant hepatic failure. Crit Care Med 19: 1362-1364
61. Hannemann L, Reinhart K, Meier-Hellmann A, Bredle D (1994) Prostacyclin in septic shock. Chest 105: 1504-1510
62. Scheeren T, Susanto F, Reinauer H, Tarnow J, Radermacher P (1994) Prostacyclin improves glucose utilization in patients with sepsis. J Crit Care 9: 175-184
63. Radermacher P, Santak B, Wüst HJ, Tarnow J, Falke KJ (1990) Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effect of pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 72: 238-244
64. Radermacher P, Santak B, Wüst HJ, Tarnow J, Falke KJ (1990) Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS. Intensive Care Med 16: 227-232
65. Rossaint R, Falke KJ, López FA, Slama K, Pison U, Zapol WM (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328: 399-405
66. Rossaint R, Slama K, Steudel W, Gerlach H, Pappert D, Veit S, Falke K (1995) Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med 21: 197-203
67. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342: 961-962
68. Bush DJ, Woods J (1992) Prostacyclin for the treatment of hypoxaemia after traumatic fat embolism. Clin Intensive Care 3: 132-133
69. Archer SL, Mike D, Crow J, Long W, Weir K (1996) A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 109: 750-755
70. Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W (1995) Effects of aerosolized prostacyclin in severe pneumonia - impact of fibrosis. Am J Respir Crit Care Med 151: 724-730
71. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 338: 1173-1174
72. 2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur Surg Res 25: 329-340
73. Bein T, Pfeifer M, Riegger GAJ, Taeger K (1994) Continuous intraarterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure. N Engl J Med 331: 335-336
74. Bein T, Metz C, Keyl C, Sendtner E, Pfeifer M (1996) Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulization system. J Cardiovasc Pharmacol 27: 583-586
75. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W (1996) Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 153: 991-996
76. Zapol WM, Falke KJ, Hurford WE, Roberts JD (1994) Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. Chest 105: 87S-91S
77. Gessler P, Nehe T, Birle A, Mueller W, Kachel W (1996) A new side effect of inhaled nitric oxide in neonates and infants with pulmonary hypertension: functional impairment of the neutrophil respiratory burst. Intensive Care Med 22: 252-258
78. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Am Intern Med 124: 820-824
79. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R (1995) Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 82: 1507-1511
80. Thomas SH, O'Doherty MJ, Fidler HM, Page CJ, Treacher DF, Nunan TO (1993) Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax 48: 154-159
81. Zwissler B, Welte M, Messmer K (1995) Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J. Cardiothorac Vasc Anesth 9: 283-289
82. Zwissler B, Rank N, Jaenicke U, Schürle B, Weite M, Reichart B, Netz H, Messmer K, Peter K (1995) Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. Anesthesiology 82: 1512-1516
83. 2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs. Intensive Care Med 22: 426-433
84. Welte M, Zwissler B, Habler O, Kleen M, Messmer K (1995) Prostacyclin aerosol and inhaled nitric oxide fail to reverse pulmonary vasoconstriction induced by thromboxane anlogue in dogs. Acta Physiol Scand 154: 395-405
85. Zobel G, Dacar D, Rödl S, Friehs I (1995) Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 38: 198-204
86. Schranz D, Zepp F, Iversen S, Wippermann C, Huth R, Zimmer B, Jüngst B-K, Oelert H (1992) Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 20: 1243-1249
87. Hausdorf G, Morf G, Berdjis F, Loebe M, Alexi V, Hebe J, Weng YG, Hetzer R, Lange PF (1992) Postoperative pulmonary hypertension in children with congenital heart disease. Z Herz-, Thorax-, Gefässchir 6: 318-322
88. Goldman AP, Delius RE, Deanfield JE, Macrae DJ (1995) Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 60: 300-306
89. Klotz K-F, Gellersen H, Hrzelinski T, Sedemund-Adib B, Gehring H (1995) Use of prostacyclin in patients with continuous hemofiltration after open heart surgery. In: Sieberth HG, Stummvoll HK, Kierdorf H (eds) Continous extracorporeal treatment in multiple organ dysfunction syndrome. Karger, Basel, pp 136-139
90. Rådegran K, Arén C, Teger-Nilsson A-C (1982) Prostacyclin infusion during extracorporeal circulation for coronary bypass. J Thorac Cardiovasc Surg 83: 205-211
91. Ponikvar R, Kandus A, Buturovic J, Kveder R (1991) Use of prostacyclin as the only anticoagulant during continous venovenous hemofiltration. In: Siebert HG, Mann H, Stummvoll HK (eds) Continous hemofiltration. Karger, Basel, pp 218-220
92. 2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol 28: 818-825
93. Camici M, Evangelisti L (1989) Heparin and prostacyclin. Angiology 40: 294-299
94. Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N (1981) Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934-939
95. Langenecker SA, Felfering M, Werba A, Mueller CM, Chiari A, Zimpfer M (1994) Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 22: 1774-1781
96. Davenport A, Will EJ, Davison AM (1994) Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pumpdriven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 66: 431-437
97. Journois D, Safran D, Castelain MH, Chanu D, Drévillon C, Barrier G (1990) Comparing the antithrombotic effects of heparin, enoxaparin and prostacyclin during continous haemofiltration. Ann Fr Anesth Réanim 9: 331-337
98. Hardy CC, Bradding P, Robinson C, Holgate ST (1988) Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma. J Appl Physiol 80: 64: 1567-1574
99. 2. J Appl Physiol 80: 191-197
100. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD, Shortino D, Crow JW (1996) A comparison of continous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334: 296-301
101. Bergman G, Daly K, Atkinson L, Rothman M, Richardson PJ, Jackson G, Jewitt DE (1981) Prostacyclin: hemodynamic and metabolic effects in patients with coronary artery disease. Lancet 1:569-572
102. Richardson A, Wells FC, Branthwaite MA (1984) Use of prostacyclin and ultrafiltration in adult respiratory distress syndrome. Intensive Care Med 10: 107-109
103. Woodcock TE (1985) Prostacyclin and ARDS. Intensive Care Med 11: 273